Cns Pharmaceuticals Inc (CNSP)

Jan 17, 2025

CNS Pharma (NASDAQ:CNSP) Stock Quotes, Forecast and News Summary - Benzinga

Jan 17, 2025

Jan 08, 2025

CNS Pharmaceuticals Advances Berubicin and TPI 287 Projects - MSN

Jan 08, 2025

Jan 08, 2025

Central Nervous System (CNS) Therapeutics Market Forecast - GlobeNewswire

Jan 08, 2025

Jan 08, 2025

Central Nervous System (CNS) Therapeutics Market Forecast (2025-2035) by Disease, Drug Class, Distribution Channel and Region - 24matins.uk

Jan 08, 2025

Jan 02, 2025

CNS Pharmaceuticals (NASDAQ:CNSP) Trading Up 6.5% – Here’s Why - Defense World

Jan 02, 2025

Dec 18, 2024

Cns Pharmaceuticals Inc (CNSP-Q) QuotePress Release - The Globe and Mail

Dec 18, 2024

Dec 18, 2024

Does Cns Pharmaceuticals Inc (NASDAQ: CNSP) Still Need To Convince Analysts? - Stocks Register

Dec 18, 2024

Dec 17, 2024

CNS Drug-Maker Reviva Announces $18M Public Offering of Common Stock and Warrants to Fund R&D - geneonline

Dec 17, 2024

Dec 17, 2024

Trevena's SWOT analysis: CNS drug developer's stock faces pivotal moment - Investing.com

Dec 17, 2024

Dec 13, 2024

CNS Pharmaceuticals Announces Upcoming Virtual Analyst and Investor Day - Defense World

Dec 13, 2024

Dec 12, 2024

Cns Pharmaceuticals Inc (NASDAQ: CNSP): An Enticing Stock To Watch - Stocks Register

Dec 12, 2024

Dec 11, 2024

CNS Pharmaceuticals Hosts Virtual Analyst and Investor Day - Nasdaq

Dec 11, 2024

Dec 06, 2024

CNS Pharmaceuticals (NASDAQ: CNSP) to Host Virtual Analyst & Investor Day on December 11 - Barchart

Dec 06, 2024

Dec 05, 2024

CNS Pharmaceuticals sets date for virtual investor event By Investing.com - Investing.com Nigeria

Dec 05, 2024

Dec 05, 2024

CNS Pharmaceuticals to Host Virtual Analyst & Investor Day on December 11, 2024 - AccessWire

Dec 05, 2024

Dec 05, 2024

CNS Pharmaceuticals to Host Virtual Investor Day: Spotlight on Breakthrough Brain Cancer Treatments - StockTitan

Dec 05, 2024

Dec 03, 2024

CNS Pharmaceuticals gains shareholder nod for reverse split, warrant repricing - Investing.com

Dec 03, 2024

Nov 25, 2024

CNS Pharmaceuticals Presents Update from Ongoing Potentially Pivotal Study of Berubicin Compared with Lomustine in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy - AccessWire

Nov 25, 2024

Nov 25, 2024

CNS Pharma's Berubicin Shows Higher Patient Retention in Pivotal GBM Trial | CNSP Stock News - StockTitan

Nov 25, 2024

Nov 23, 2024

CNS Pharmaceuticals Participates in Virtual Investor KOL Connect Segment - GuruFocus.com

Nov 23, 2024

Nov 23, 2024

CNS Pharmaceuticals (NASDAQ:CNSP) Stock Price Down 4.3% – Here’s What Happened - Defense World

Nov 23, 2024

Nov 23, 2024

CNS Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 23, 2024

Nov 19, 2024

CNS Pharmaceuticals (NASDAQ: CNSP) to Present Berubicin Trial Update at Society for Neuro-Oncology Annual Meeting - Barchart

Nov 19, 2024

Nov 18, 2024

CNS Pharmaceuticals (NASDAQ: CNSP) Advances Glioblastoma Treatment With Berubicin - Barchart

Nov 18, 2024

Nov 18, 2024

CNS Pharmaceuticals to Present Berubicin GBM Trial Data at SNO 2024 Annual Meeting | CNSP Stock News - StockTitan

Nov 18, 2024

Nov 18, 2024

CNS Pharmaceuticals Announces Abstract Accepted for Poster Presentation at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO 2024) - AccessWire

Nov 18, 2024

Nov 15, 2024

CNS Pharmaceuticals Reports Third Quarter 2024 Financial Results - AccessWire

Nov 15, 2024

Nov 15, 2024

CNS Pharmaceuticals Completes 252-Patient Enrollment in Pivotal Brain Cancer Study | CNSP Stock News - StockTitan

Nov 15, 2024

Nov 15, 2024

CNS Pharmaceuticals Inc (CNSP) Quarterly 10-Q Report - Quartzy

Nov 15, 2024

Nov 15, 2024

ARMISTICE CAPITAL, LLC Acquires New Stake in CNS Pharmaceuticals Inc - GuruFocus.com

Nov 15, 2024

Nov 14, 2024

CNS Pharmaceuticals: Financial Results and Strategic Moves - TipRanks

Nov 14, 2024

Nov 13, 2024

ACADIA Pharmaceuticals' SWOT analysis: mixed results for CNS drug stock - Investing.com

Nov 13, 2024

Nov 06, 2024

CNS Pharmaceuticals’ $3 Million Common Stock Offering - Global Legal Chronicle

Nov 06, 2024

Nov 06, 2024

Reviva Pharma to Present Breakthrough Phase 3 Schizophrenia Drug Data at CNS Summit - StockTitan

Nov 06, 2024

Nov 05, 2024

Sage Therapeutics' SWOT analysis: stock faces challenges amid CNS drug market shifts - Investing.com

Nov 05, 2024

Nov 04, 2024

CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment - AccessWire

Nov 04, 2024

Nov 03, 2024

CNS Pharmaceuticals Receives Temporary Exception from NASDAQ Regarding Minimum Bid Price Requirement - Defense World

Nov 03, 2024

Nov 01, 2024

CNS Pharmaceuticals granted Nasdaq compliance extension By Investing.com - Investing.com South Africa

Nov 01, 2024

Nov 01, 2024

CNS Pharmaceuticals Granted Exception by Nasdaq to Regain Compliance with Minimum Bid Price Requirement - Yahoo Finance

Nov 01, 2024

Nov 01, 2024

CNS Pharmaceuticals granted Nasdaq compliance extension - Investing.com

Nov 01, 2024

Nov 01, 2024

CNSPCNS Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan

Nov 01, 2024

Oct 31, 2024

Avadel Pharmaceuticals Announces Favorable Ruling in Administrative Procedure Act Litigation - The Manila Times

Oct 31, 2024

Oct 25, 2024

Stocks Under Ten Cents to Watch in October 2024 CNSP, QLGN, AKTS, CBDW, RJDG - Financial Content

Oct 25, 2024

Oct 23, 2024

CNS Pharmaceuticals faces NASDAQ delisting over price rule By Investing.com - Investing.com Australia

Oct 23, 2024

Oct 23, 2024

CNS Pharmaceuticals secures $3 million in registered direct offering - Investing.com

Oct 23, 2024